Diagnostic application of BAP1 immunohistochemistry to differentiate pleural mesothelioma from metastatic pleural tumors

Abstract

Malignant pleural mesothelioma (MPM) is the most common primary pleural tumor and an aggressive neoplasm that arises from mesothelium of the pleura. The prognosis is poor with the overall median survival of 9-11 months¹. For the diagnosis of MPM, differentiating MPM from pleural metastatic tumors is important.

This article is protected by copyright. All rights reserved.

http://ift.tt/2uCvhhr